Period:
Draw Mode:
| Volume | 200 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Erasca Inc | ERAS | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.28 | 9.46% | 3.24 | 05:09:17 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 2.96 |
| Trades | Volume | Avg Volume | 52 Week Range |
|---|---|---|---|
| 2 | 200 | - | 2.65 - 10.74 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 05:09:17 | formt | 100 | $ 3.24 | USD |
Erasca Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 487.91M | 150.59M | 105.60M | $ - | $ - | -1.99 | -4.20 |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | - | 1.93M | 0.90% |
Erasca News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ERAS Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 2.94 | 3.2199 | 2.65 | 2.83 | 1,117,929 | 0.30 | 10.2% |
| 1 Month | 3.47 | 3.58 | 2.65 | 3.12 | 1,309,107 | -0.23 | -6.63% |
| 3 Months | 4.41 | 4.57 | 2.65 | 3.59 | 1,087,564 | -1.17 | -26.53% |
| 6 Months | 7.84 | 9.25 | 2.65 | 4.78 | 1,027,131 | -4.60 | -58.67% |
| 1 Year | 9.50 | 10.74 | 2.65 | 5.67 | 765,911 | -6.26 | -65.89% |
| 3 Years | 15.90 | 24.47 | 2.65 | 8.78 | 681,146 | -12.66 | -79.62% |
| 5 Years | 15.90 | 24.47 | 2.65 | 8.78 | 681,146 | -12.66 | -79.62% |
Erasca Description
| Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's pipeline includes two clinical-stage programs (ERK and SHP2 inhibitors), two preclinical-stage programs (CNS-penetrant KRAS G12C and EGFR inhibitors), and seven discovery-stage programs targeting other key oncogenic drivers. |